Value
3.6/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 0.0 |
| Analyst target | 6.0 |
SEPN · Why this verdict
Why Septerna (SEPN) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.5/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Septerna is a pre-revenue biotech with elite cash conversion (FCF margin 33%) and strong analyst support, but a consistent earnings miss streak and high short interest of 11% create meaningful downside risk that outweighs the 10.5% upside at current prices.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Analysts carry a consensus buy rating with 27% upside to their price target, and a strong current ratio of 8.3 suggests the company is well-capitalized to pursue its development pipeline without near-term funding pressure. Sentiment breakdown | The analyst consensus price target rises above $45 over the next 12 months as pipeline progress provides positive catalysts. | →Stable |
| CounterWith only 9 analysts covering the stock and the signal flagged as dampened, the consensus may lack the depth needed to be a reliable valuation anchor. | ||
Despite reporting GAAP losses, the company generates a 33% free cash flow margin with an FCF yield of 1.5%, and an exceptional Rule of 40 score of over 12,000, suggesting the business structure supports cash sustainability in the near term. Quality breakdown | Free cash flow margin remains above 20% over the next 12 months as the company controls operating expenses. | →Stable |
| CounterFCF generation for a pre-revenue biotech can be misleading; it may reflect low spending rather than business quality, and a single pipeline setback could rapidly consume cash reserves. | ||
Implied volatility of 103% and a put-to-call ratio of 0.115 reflect extreme uncertainty around future outcomes, with the options market pricing in large potential swings that are inconsistent with a confident long thesis. Risk breakdown | Implied volatility falls below 70% over the next 12 months as the company delivers more predictable results. | →Stable |
| CounterExtremely low put-to-call ratios can signal call-side speculation rather than genuine conviction, which could unwind quickly on negative news. | ||
Short interest stands at 11% of the float, and the company has missed earnings estimates in 3 of its last 4 quarters with an average negative surprise of 56%, a combination that raises the probability of sharp downside moves on poor results. Key risks | Short interest falls below 8% over the next 12 months as earnings results improve and the bear case weakens. | →Stable |
| CounterHigh short interest can create powerful short-covering rallies if even one quarter delivers a strong positive surprise, as the most recent quarter demonstrated with a 56.9% beat. | ||
Analysts carry a consensus buy rating with 27% upside to their price target, and a strong current ratio of 8.3 suggests the company is well-capitalized to pursue its development pipeline without near-term funding pressure.
→StableSentiment breakdown
- Expectation
- The analyst consensus price target rises above $45 over the next 12 months as pipeline progress provides positive catalysts.
CounterWith only 9 analysts covering the stock and the signal flagged as dampened, the consensus may lack the depth needed to be a reliable valuation anchor.
Despite reporting GAAP losses, the company generates a 33% free cash flow margin with an FCF yield of 1.5%, and an exceptional Rule of 40 score of over 12,000, suggesting the business structure supports cash sustainability in the near term.
→StableQuality breakdown
- Expectation
- Free cash flow margin remains above 20% over the next 12 months as the company controls operating expenses.
CounterFCF generation for a pre-revenue biotech can be misleading; it may reflect low spending rather than business quality, and a single pipeline setback could rapidly consume cash reserves.
Implied volatility of 103% and a put-to-call ratio of 0.115 reflect extreme uncertainty around future outcomes, with the options market pricing in large potential swings that are inconsistent with a confident long thesis.
→StableRisk breakdown
- Expectation
- Implied volatility falls below 70% over the next 12 months as the company delivers more predictable results.
CounterExtremely low put-to-call ratios can signal call-side speculation rather than genuine conviction, which could unwind quickly on negative news.
Short interest stands at 11% of the float, and the company has missed earnings estimates in 3 of its last 4 quarters with an average negative surprise of 56%, a combination that raises the probability of sharp downside moves on poor results.
→StableKey risks
- Expectation
- Short interest falls below 8% over the next 12 months as earnings results improve and the bear case weakens.
CounterHigh short interest can create powerful short-covering rallies if even one quarter delivers a strong positive surprise, as the most recent quarter demonstrated with a 56.9% beat.
Per-dimension breakdown
Quality
5.0/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 10.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 8.3 |
| FCF quality | 9.2 |
| Moat | 5.8 |
| Rule of 40 | 9.5 |
| Piotroski F | 6.7 |
- ▸FCF-positive despite GAAP loss (FCF margin 33%, FCF yield 1.5%)
- ▸Rule of 40: 12044 (elite)
Growth
5.0/10data confidence 50%Momentum
4.7/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 8.6 |
| OBV | 1.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
7.5/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 8.0 |
| Price target | 8.3 |
| erm sentiment | 5.6 |
- ▸Light analyst coverage (9.0) — signal dampened
- ▸Analyst upside: 27%
Insider
3.8/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 5.0 |
- ▸Modest insider selling — $842,906 (0.052% of mkt cap)
Peer rank
4.6/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 2.8 |
| quality rank | 4.1 |
| growth rank | 10.0 |
- ▸Industry growth leader
Technical
4.4/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 2.3 |
| support resistance | 1.8 |
| 52w position | 9.0 |
Risk (lower is worse)
1.3/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 4.3 |
| days to cover | 1.6 |
| volatility | 0.0 |
| put call | 0.0 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| debt equity | 0.0 |
- ▸Elevated put/call: 25.10
- ▸High IV: 123%
- ▸Above max pain $19
Catalyst
2.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
- ▸Earnings concerns: 1B/3M
How the verdict was assembled
Engine trigger
Extreme risk factors.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:4.7>=4.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:46d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:0.7<1.5@spot
Warning (1)
- MOMENTUM:4.7<5.5 (soft — BUY_NOW allowed but watch)
Reward-to-Risk
0.70
Upside
+10.5%
Downside
15.0%
Sizing output
AVOID
SetupBREAKOUT — Golden cross, above all MAs, RSI 68, MACD bullish
EdgeNO_EDGE — No clear edge identified
SuitabilityAGGRESSIVE — MCap $1.6B<$5B
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Sentiment at 7.5 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:0.7<1.5@spot.
The strongest dimensions are Sentiment at 7.5, Quality at 5.0, and Growth at 5.0; the weakest are Risk (lower is worse) at 1.3, Catalyst at 2.5, and Value at 3.6. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 0.70 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Despite reporting GAAP losses, the company generates a 33% free cash flow margin with an FCF yield of 1.5%, and an exceptional Rule of 40 score of over 12,000, suggesting the business structure supports cash sustainability in the near term.
Trip ifFree cash flow margin falls below 15% for 2 consecutive quarters, indicating cash burn has accelerated beyond sustainable levels.
- P2Short interest stands at 11% of the float, and the company has missed earnings estimates in 3 of its last 4 quarters with an average negative surprise of 56%, a combination that raises the probability of sharp downside moves on poor results.
Trip ifShort interest rises above 15% of the float, signaling increased bearish conviction from institutional investors.
- P3Analysts carry a consensus buy rating with 27% upside to their price target, and a strong current ratio of 8.3 suggests the company is well-capitalized to pursue its development pipeline without near-term funding pressure.
Trip ifAnalyst consensus price target falls below $32, more than 11% below current levels, following a pipeline setback.
- P4Implied volatility of 103% and a put-to-call ratio of 0.115 reflect extreme uncertainty around future outcomes, with the options market pricing in large potential swings that are inconsistent with a confident long thesis.
Trip ifImplied volatility rises above 120%, more than 17 percentage points above current levels, ahead of a scheduled data readout.